Hyperbaric oxygen therapy reduces inflammation and promotes remission in Crohn's disease
Hyperbaric oxygen therapy reduces inflammation and promotes remission in Crohn's disease
Understanding Crohn's disease and how hyperbaric oxygen therapy helps
Crohn's disease is a chronic inflammatory bowel disease that causes transmural inflammation in the gastrointestinal tract, most commonly affecting the terminal ileum and colon. Symptoms include abdominal pain, persistent diarrhea, weight loss, fatigue and nutritional deficiencies. The condition results from complex interactions between genetic predisposition, immune system dysfunction and environmental factors.
Complications can include intestinal strictures, fistulas, abscesses and perianal disease that significantly impact quality of life. Standard treatments include anti-inflammatory drugs, immunosuppressants, biologics and surgery, but many patients develop treatment-resistant disease. HBOT offers a complementary approach by directly reducing intestinal inflammation, promoting tissue healing and supporting remission in patients who have not responded adequately to conventional therapies.
Chronic abdominal pain, cramping and diarrhea
Weight loss, fatigue and nutritional deficiencies
Fistulas, strictures and perianal complications
Treatment-resistant inflammation requiring escalating medications
How pressurized oxygen calms intestinal inflammation and promotes healing
HBOT addresses the inflammatory cascade driving Crohn's disease while supporting tissue repair in damaged intestinal tissue.
Significantly reduces inflammation markers and disease activity
Promotes clinical and steroid-free remission
Heals treatment-resistant wounds and fistulas
Safe and well-tolerated adjunct therapy
Reduces intestinal oxygen deprivation
Supports immune system modulation
For Providers
Clinical evidence for HBOT in Crohn's disease and inflammatory bowel conditions
Hyperbaric oxygen therapy has demonstrated significant benefits for Crohn's disease and inflammatory bowel conditions through multiple clinical pathways.
Inflammation reduction: HBOT reduces key markers of inflammation including C-reactive protein (CRP) and improves disease activity indices like the Crohn's Disease Activity Index (CDAI). By suppressing pro-inflammatory cytokines and down-regulating inflammatory gene expression, HBOT addresses the underlying immune-mediated inflammation that drives Crohn's disease progression.
Clinical remission: Studies demonstrate that HBOT fosters both clinical and steroid-free remission in refractory Crohn's disease. Approximately 50% of patients show radiological improvements confirmed by imaging, indicating structural healing beyond symptomatic relief. Between 78% and 88% of Crohn's patients who receive HBOT experience significant improvement in their condition.
Wound and fistula healing: For patients with severe complications including perineal pseudotumors and treatment-resistant perianal disease, HBOT supports complete healing post-surgery with no hospital readmissions during follow-up. The ability to heal complex GI wounds that resist conventional treatment makes HBOT particularly valuable for patients with complicated Crohn's disease.
Tissue oxygenation: Inflamed intestinal tissue in Crohn's disease becomes hypoxic due to vascular damage and edema. HBOT dramatically increases oxygen delivery to these tissues, supporting mucosal healing, reducing bacterial translocation and promoting the regeneration of healthy intestinal lining.
Safety profile: Clinical data consistently demonstrates that HBOT is safe and well-tolerated in IBD patients, with only mild side effects reported. This favorable safety profile makes it a viable adjunct therapy for patients who cannot tolerate aggressive immunosuppression or who have exhausted conventional treatment options.
HBOT Reduces Inflammation and Disease Activity in Crohn’s Disease: CRP and CDAI Scores Improve Significantly
Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in Crohn’s disease
After 10 sessions of HBOT, CRP levels (P = 0.004) and CDAI scores (P = 0.044) significantly decreased in patients undergoing treatment, though ESR levels remained unchanged (P = 0.251). Fecal calprotectin levels improved in three patients, with normalization in one case, while hemoglobin levels showed a mild, non-significant decrease (P > 0.05). These findings suggest HBOT may reduce inflammation and disease activity in specific cases. Li Y, Sun R, Lai C, et al. Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in Crohn’s disease. Journal of Translational Medicine. 2024;22:1-14. doi:10.1186/s12967-024-05317-1Clinical Effectiveness of Hyperbaric Oxygen Therapy in Complex Wounds
Hyperbaric Oxygen Therapy (HBOT) Shows Promising Results for Refractory Small Bowel Crohn’s Disease, with Significant Clinical Remission
In this pilot study, 14 patients with stricturing small bowel Crohn’s disease (CD) refractory to conventional treatments underwent HBOT. Over a median of 4 weeks and 11 sessions per patient (range, 3–20), 64.2% achieved clinical response, and 50–64.2% reached clinical remission at 2 and 6 months, respectively. Steroid-free remission occurred in 57% of patients, with 50% showing radiological improvement. SIBD scores improved significantly at 2 months (P = 0.03). HBOT was well-tolerated, except for one case of hemotympanum, suggesting it is a safe and potentially effective therapy for refractory CD. Kante B, Sahu P, Kedia S, et al. Efficacy and tolerability of hyperbaric oxygen therapy in small bowel stricturing Crohn’s disease: a pilot study. Intestinal Research. 2022;20(2):231-239. doi:10.5217/ir.2021.00056Hyperbaric oxygen therapy for the management of chronic wounds: patient selection and perspectives.
HBOT as Adjunctive Therapy for Extreme Perineal Pseudotumors: Successful Healing and No Recurrence at Long-Term Follow-Up
This study evaluated the use of preoperative and postoperative hyperbaric oxygen therapy (HBOT) in four patients with extreme perineal pseudotumors (PPS) refractory to prior interventions. Patients underwent up to 30 preoperative HBOT sessions followed by abdominoperineal PPS excision and RAM flap reconstruction, with additional postoperative HBOT sessions in two cases. All patients achieved complete perineal healing within a median of 2.5 months, with no hospital readmissions for PPS at a median follow-up of 35 months. HBOT appears to be a safe and effective adjunct to surgical management for treatment-resistant PPS. Chan XH, Koh CE, Glover M, Bryson P, Travis SP, Mortensen NJ. Healing under pressure: hyperbaric oxygen and myocutaneous flap repair for extreme persistent perineal sinus after proctectomy for inflammatory bowel disease. Colorectal Dis. 2014;16(3):186-190. doi:10.1111/codi.12500Patient experiences with HBOT for inflammatory conditions
Lisa, 44
Jennifer, 68
Your path from Crohn's flares to sustained remission
We design a personalized HBOT protocol based on your disease severity, symptoms and treatment history.
Comprehensive GI assessment and treatment planning
Our medical team reviews your Crohn's history, current medications, disease activity and any complications to create a targeted HBOT plan coordinated with your gastroenterologist.
Comfortable daily sessions in our pressurized chambers
You breathe 100% oxygen in a pressurized chamber for approximately 90 minutes per session. Protocols typically involve 30 to 40 sessions depending on disease severity.
Measurable reduction in inflammation and symptoms
We track symptom improvement and coordinate with your GI team on lab markers. Most patients experience progressive reduction in pain, diarrhea and disease activity scores.
Frequently Asked Questions
Answers to the questions patients ask most about hyperbaric oxygen therapy for Crohn's disease and inflammatory bowel conditions.
HBOT delivers oxygen under pressure that reduces intestinal inflammation, lowers C-reactive protein levels and improves disease activity scores. It promotes mucosal healing in the gut, supports steroid-free remission and helps heal treatment-resistant complications like fistulas and perianal disease. Studies show 78-88% of Crohn's patients experience significant improvement.
Take control of your Crohn's disease today
Schedule a free consultation to discuss how hyperbaric oxygen therapy can reduce your inflammation, promote healing and help you achieve lasting remission.
